Table 1.

General characteristics of SARS-CoV-2 vaccinated adults aged 18–64 years up to two months following the first or second dose by vaccination brand and number of doses (n = 2,412).

n (%), unless otherwise specified	Comirnaty		Spikevax		Vaxzevria		Janssen	P-value***
Doses	1	2	1	2	1	2	1
N	974	466	222	124	111	298	217
Sex								< 0.001
Male	407 (42%)	154 (33%)	87 (39%)	31 (25%)	47 (42%)	98 (33%)	82 (38%)
Female	567 (58%)	312 (67%)	135 (61%)	93 (75%)	64 (58%)	200 (67%)	135 (62%)
Age in years								< 0.001
18–29	68 (7%)	47 (10%)	18 (8%)	11 (9%)	3 (3%)	15 (5%)	26 (12%)
30–44	332 (34%)	101 (22%)	78 (35%)	49 (40%)	5 (5%)	40 (13%)	49 (23%)
45–64	574 (59%)	318 (68%)	126 (57%)	64 (52%)	103 (93%)	243 (82%)	142 (65%)
Healthcare worker								< 0.001
No	841 (86%)	297 (64%)	184 (83%)	57 (46%)	97 (87%)	179 (60%)	157 (72%)
Yes	133 (14%)	169 (36%)	38 (17%)	67 (54%)	14 (13%)	119 (40%)	60 (28%)
Comorbidities								< 0.001
Risk group*	236 (24%)	193 (41%)	50 (23%)	39 (31%)	48 (43%)	106 (36%)	32 (15%)
None/other**	738 (76%)	273 (59%)	172 (77%)	85 (69%)	63 (57%)	192 (64%)	185 (85%)
Infection history								< 0.001
No	791 (81%)	408 (88%)	175 (79%)	108 (87%)	101 (91%)	265 (89%)	186 (86%)
Yes	183 (19%)	58 (12%)	47 (21%)	16 (13%)	10 (9%)	33 (11%)	31 (14%)
Median vaccination interval in days (IQR)		35 (28 – 35)		33 (28—35)		77 (69 – 77)

*High risk comorbidities: asthma or other lung disease, cardiovascular disease, diabetes, (history of) cancer, history of transplantation, kidney disease, immune disease, splenectomy, liver disease, rheumatoid arthritis, intestinal disease, neurological disease, or other (open field). Persons with these comorbidities were prioritized during the vaccination campaign in the Netherlands as they were considered high risk for severe COVID-19.

**Other comorbidities: hay fever, skin disease or allergies.

***Chi-squared tests were used to test for statistical differences between groups.

IQR: interquartile range.